These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 36232697

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.
    Borgo C, D'Amore C, Capurro V, Tomati V, Sondo E, Cresta F, Castellani C, Pedemonte N, Salvi M.
    Cell Mol Life Sci; 2022 Mar 16; 79(4):192. PubMed ID: 35292885
    [Abstract] [Full Text] [Related]

  • 5. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
    Becq F, Mirval S, Carrez T, Lévêque M, Billet A, Coraux C, Sage E, Cantereau A.
    Eur Respir J; 2022 Feb 16; 59(2):. PubMed ID: 34266939
    [Abstract] [Full Text] [Related]

  • 6. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles.
    Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, Sommerburg O, Dittrich AM, Tümmler B, Mall MA.
    Am J Respir Crit Care Med; 2022 Mar 01; 205(5):540-549. PubMed ID: 34936849
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
    Abou Alaiwa MH, Launspach JL, Grogan B, Carter S, Zabner J, Stoltz DA, Singh PK, McKone EF, Welsh MJ.
    JCI Insight; 2018 Aug 09; 3(15):. PubMed ID: 30089726
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS, Jiang J, Ahmadi S, Lew A, Laselva O, Xia S, Bartlett C, Ip W, Wellhauser L, Ouyang H, Gonska T, Moraes TJ, Bear CE.
    Mol Pharmacol; 2019 Oct 09; 96(4):515-525. PubMed ID: 31427400
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.
    Morrison CB, Shaffer KM, Araba KC, Markovetz MR, Wykoff JA, Quinney NL, Hao S, Delion MF, Flen AL, Morton LC, Liao J, Hill DB, Drumm ML, O'Neal WK, Kesimer M, Gentzsch M, Ehre C.
    Eur Respir J; 2022 Feb 09; 59(2):. PubMed ID: 34172469
    [Abstract] [Full Text] [Related]

  • 15. Pulmonary Ionocytes Regulate Airway Surface Liquid pH in Primary Human Bronchial Epithelial Cells.
    Luan X, Henao Romero N, Campanucci VA, Le Y, Mustofa J, Tam JS, Ianowski JP.
    Am J Respir Crit Care Med; 2024 Sep 15; 210(6):788-800. PubMed ID: 38573173
    [Abstract] [Full Text] [Related]

  • 16. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles.
    Graeber SY, Renz DM, Stahl M, Pallenberg ST, Sommerburg O, Naehrlich L, Berges J, Dohna M, Ringshausen FC, Doellinger F, Vitzthum C, Röhmel J, Allomba C, Hämmerling S, Barth S, Rückes-Nilges C, Wielpütz MO, Hansen G, Vogel-Claussen J, Tümmler B, Mall MA, Dittrich AM.
    Am J Respir Crit Care Med; 2022 Aug 01; 206(3):311-320. PubMed ID: 35536314
    [Abstract] [Full Text] [Related]

  • 17. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM.
    Drugs; 2019 Dec 01; 79(18):2001-2007. PubMed ID: 31784874
    [Abstract] [Full Text] [Related]

  • 18. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.
    Ferreira FC, Buarque CD, Lopes-Pacheco M.
    Molecules; 2024 Feb 10; 29(4):. PubMed ID: 38398574
    [Abstract] [Full Text] [Related]

  • 19. The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs.
    Sondo E, Cresta F, Pastorino C, Tomati V, Capurro V, Pesce E, Lena M, Iacomino M, Baffico AM, Coviello D, Bandiera T, Zara F, Galietta LJV, Bocciardi R, Castellani C, Pedemonte N.
    Int J Mol Sci; 2022 Mar 15; 23(6):. PubMed ID: 35328596
    [Abstract] [Full Text] [Related]

  • 20. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K, Taylor-Cousar JL.
    Ther Adv Respir Dis; 2015 Dec 15; 9(6):313-26. PubMed ID: 26416827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.